DK132303B - Fremgangsmåde til fremstilling af en lægemiddelform med retarderende virkning. - Google Patents

Fremgangsmåde til fremstilling af en lægemiddelform med retarderende virkning.

Info

Publication number
DK132303B
DK132303B DK101271AA DK101271A DK132303B DK 132303 B DK132303 B DK 132303B DK 101271A A DK101271A A DK 101271AA DK 101271 A DK101271 A DK 101271A DK 132303 B DK132303 B DK 132303B
Authority
DK
Denmark
Prior art keywords
preparation
pharmaceutical form
retarding effect
retarding
effect
Prior art date
Application number
DK101271AA
Other languages
English (en)
Other versions
DK132303C (da
Inventor
W Fylberth
E Neitzer
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of DK132303B publication Critical patent/DK132303B/da
Application granted granted Critical
Publication of DK132303C publication Critical patent/DK132303C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
DK101271A 1970-03-05 1971-03-04 Fremgangsmade til fremstilling af en legemiddelform med retarderende virkning DK132303C (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2010416A DE2010416B2 (de) 1970-03-05 1970-03-05 Oral anwendbare Arzneiform mit Retardwirkung

Publications (2)

Publication Number Publication Date
DK132303B true DK132303B (da) 1975-11-24
DK132303C DK132303C (da) 1976-04-26

Family

ID=5764197

Family Applications (1)

Application Number Title Priority Date Filing Date
DK101271A DK132303C (da) 1970-03-05 1971-03-04 Fremgangsmade til fremstilling af en legemiddelform med retarderende virkning

Country Status (13)

Country Link
US (1) US3835221A (da)
JP (1) JPS5331930B1 (da)
AT (1) AT305498B (da)
BE (1) BE763735A (da)
CA (1) CA977680A (da)
DE (1) DE2010416B2 (da)
DK (1) DK132303C (da)
ES (1) ES388698A1 (da)
FR (1) FR2085672B1 (da)
GB (1) GB1326995A (da)
NL (1) NL169680C (da)
SE (1) SE377886B (da)
ZA (1) ZA711412B (da)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
FR2377196A1 (fr) * 1977-01-13 1978-08-11 Lipha Composition medicamenteuse a usage oral
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
FR2397840B1 (da) * 1977-07-22 1981-03-20 Cherqui Jean
US4153677A (en) * 1978-05-18 1979-05-08 Sterling Drug Inc. Controlled-release composition
GB1584130A (en) * 1978-05-30 1981-02-04 Wyeth John & Brother Ltd Indole derivatives
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
JPS55129219A (en) * 1979-03-29 1980-10-06 Asahi Chem Ind Co Ltd Slow-releasing preparation
FR2454804B1 (fr) * 1979-04-26 1986-11-21 Sanofi Sa Medicament a base de dihydroergotoxine et son procede de preparation
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
DE3278491D1 (en) * 1981-07-15 1988-06-23 Key Pharma Sustained release theophyline
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
WO1984000004A1 (en) * 1982-06-14 1984-01-05 Key Pharma Sustained release aspirin
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
DE3382392D1 (de) * 1982-07-09 1991-10-02 Key Pharma Dosierungsart zur dauerhaften verabreichung von chinidin.
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
GB2159714B (en) * 1984-06-04 1988-05-05 Sterwin Ag Pharmaceutical composition of sparingly soluble medicament and method for its preparation
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
DE3486409T2 (de) * 1984-08-17 1996-04-25 Wellcome Found Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4629620A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
CA1268710A (en) * 1984-11-06 1990-05-08 Nagin K. Patel Drug in bead form and process for preparing same
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
IL110035A0 (en) * 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
FR2766367B1 (fr) * 1997-07-22 2000-03-31 Plantes Et Medecines Granules homeopathiques et procede de fabrication
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6254888B1 (en) 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
AU2001268159B2 (en) * 2000-06-02 2005-09-15 Eisai Inc. Delivery systems for bioactive agents
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
AU2002225763A1 (en) 2000-11-28 2002-06-11 Fmc Corporation Edible pga(propylene glycol alginate) coating composition
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
EP2957281A1 (en) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
DE602004031096D1 (de) 2003-03-26 2011-03-03 Egalet As Morphin-system mit kontrollierter freisetzung
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
PT2535044T (pt) 2006-01-27 2020-03-26 Univ California Cistamina e bitartarato de cisteamina revestidas entericamente
CA2674536C (en) * 2007-01-16 2016-07-26 Egalet A/S Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
PT2276485E (pt) 2008-04-24 2014-10-20 Bristol Myers Squibb Co Utilização de epotilona d no tratamento de doenças tauassociadas que compreendem a doença de alzheimer
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
PL2665477T3 (pl) 2011-01-20 2016-05-31 Bionevia Pharmaceuticals Inc Kompozycje epalrestatu lub jego pochodnej o zmodyfikowanym uwalnianiu i sposoby ich stosowania
SG10201800159QA (en) 2011-11-22 2018-02-27 Univ California Cysteamine and/or cystamine for treating ischemic injury
DK2861599T3 (da) 2012-06-18 2020-03-02 Principia Biopharma Inc Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
CA2971109A1 (en) 2014-12-24 2016-06-30 Principia Biopharma Inc. Site specific dosing of a btk inhibitor
UA124090C2 (uk) 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
ES2770113T3 (es) 2015-07-02 2020-06-30 Horizon Orphan Llc Análogos de la cisteamina resistentes a la ADO y sus usos
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
KR20180082613A (ko) * 2015-12-08 2018-07-18 아디아 바이오사이언스즈 인크. Urat1의 강력한 억제제를 포함하는 약학 조성물
BR112018077503A2 (pt) 2016-06-29 2019-04-09 Principia Biopharma Inc. formulações de liberação modificada de 2-[3-[4-amino-3-(2-fluoro-4- fenoxi-fenil)pirazolo [3,4-d]pirimidin-1-il]piperidino-1- carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il] pent-2-enenitrila
KR20220130179A (ko) 2020-01-20 2022-09-26 젠자임 코포레이션 재발성 다발성 경화증(rms)에 대한 치료용 티로신 키나제 저해제
JP2023522623A (ja) 2020-04-17 2023-05-31 ジェンザイム・コーポレーション 全身性過炎症反応を伴う状態の処置に使用するエクリタセルチブ
EP4294427A1 (en) 2021-02-19 2023-12-27 DuPont Nutrition Biosciences ApS Compositions for gut health
TW202302086A (zh) 2021-02-23 2023-01-16 日商大塚製藥股份有限公司 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法
TW202421141A (zh) 2022-06-30 2024-06-01 美商健臻公司 用於多發性硬化症及重症肌無力之治療性酪胺酸激酶抑制劑
WO2024040043A1 (en) 2022-08-16 2024-02-22 International N&H Denmark Aps Expression systems for phosphatases
TW202412768A (zh) 2022-09-02 2024-04-01 日商大塚製藥股份有限公司 以1-(萘-2-基)-3-氮雜雙環[3.1.0]己烷治療中樞神經系統病症之方法
WO2024064653A1 (en) 2022-09-20 2024-03-28 Dupont Nutrition Biosciences Aps Variant anti-viral polypeptides
WO2024081168A1 (en) 2022-10-11 2024-04-18 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for multiple sclerosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2410417A (en) * 1944-03-04 1946-11-05 Lever Brothers Ltd Vitamin and mineral dietary supplement and method of making
CH283585A (de) * 1950-03-15 1952-06-15 Hoffmann La Roche Zur Herstellung von Tablettenüberzügen geeignetes Gemisch.
FR1017117A (fr) * 1950-05-04 1952-12-02 Trialgol Lab Procédé de conditionnement à l'état de poudre de substances destinées à l'ingestion et produits en résultant
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US2811483A (en) * 1954-12-09 1957-10-29 Pfizer & Co C Pharmaceutical composition and process for preparing the same
US2853420A (en) * 1956-01-25 1958-09-23 Lowey Hans Ethyl cellulose coatings for shaped medicinal preparations
US2852433A (en) * 1956-03-07 1958-09-16 Eastman Kodak Co Method of making enteric medicament compositions
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
DE1228757B (de) * 1962-06-28 1966-11-17 Haessle Ab Verfahren zur Herstellung eines in Wasser und Magensaft rasch zerfallenden UEberzuges auf festen Arzneiformen
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
DE1216486B (de) * 1964-04-23 1966-05-12 Merck Ag E Verfahren zur Herstellung von Dragees
US3365365A (en) * 1965-08-09 1968-01-23 Hoffmann La Roche Repeat action pharmaceutical compositions in the form of discrete beadlets
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets

Also Published As

Publication number Publication date
AT305498B (de) 1973-02-26
NL7102590A (da) 1971-09-07
DE2010416B2 (de) 1979-03-29
CA977680A (en) 1975-11-11
NL169680B (nl) 1982-03-16
SE377886B (da) 1975-08-04
DK132303C (da) 1976-04-26
ES388698A1 (es) 1974-02-16
DE2010416A1 (de) 1971-09-16
JPS5331930B1 (da) 1978-09-05
GB1326995A (en) 1973-08-15
FR2085672A1 (da) 1971-12-31
BE763735A (fr) 1971-09-03
FR2085672B1 (da) 1974-04-12
ZA711412B (en) 1971-11-24
US3835221A (en) 1974-09-10
NL169680C (nl) 1982-08-16

Similar Documents

Publication Publication Date Title
DK132303B (da) Fremgangsmåde til fremstilling af en lægemiddelform med retarderende virkning.
DK134316B (da) Fremgangsmåde til fremstilling af methylsubstituerede cuinoner.
DK129339B (da) Analogifremgangsmåde til fremstilling af N-aminophenylamidiner.
DK123357B (da) Analogifremgangsmåde til fremstilling af N(6)-benzyl-adenosin-derivater.
DK137955B (da) Analogifremgangsmåde til fremstilling af morphinan-derivater.
DK135455B (da) Fremgangsmåde til fremstilling af 7-halogen-7-desoxythiolincosaminider.
DK560675A (da) Fremgangsmade til fremstilling af thiopyrimidinderivater
DK134489B (da) Fremgangsmåde til fremstilling af alkyl-7-desoxy-7(S)-substituerede-alfa-thiolincosaminider.
DK128496B (da) Fremgangsmåde til fremstilling af 5-fluoruracilderivater.
DK137189B (da) Fremgangsmåde til fremstilling af quinolinderivater.
DK130467B (da) Fremgangsmåde til fremstilling af erythromycylaminer.
DK122708B (da) Fremgangsmåde til fremstilling af farmaceutiske tabletter med langvarig virkning.
DK128895B (da) Fremgangsmåde til fremstilling af pregnanderivater.
DK127977B (da) Fremgangsmåde til fremstilling af 6α-methyl-19-nor-pregnener.
DK126998B (da) Analogifremgangsmåde til fremstilling af amino-s-triazolylbenzensulfonamidforbindelser.
DK138490B (da) Fremgangsmåde til fremstilling af prostadiensyrederivater.
DK128205B (da) Fremgangsmåde til fremstilling af 1-aryloxy-2-propanoler.
DK137181B (da) Analogifremgangsmåde til fremstilling af 3-amino-kinolinderivater.
DK129453B (da) Analogifremgangsmåde til fremstilling af 1-aminoisoquinoliner.
DK126323B (da) Fremgangsmåde til fremstilling af 3β-hydroxy-5α-cardenolider eller -bufadienolider.
DK126509B (da) Fremgangsmåde til fremstilling af zearalenon.
DK125388B (da) Fremgangsmåde til fremstilling af phenylaminoethanolderivater.
DK137860B (da) Analogifremgangsmåde til fremstilling af triazolobenzodiazepin-5N-oxydderivater.
DK126034B (da) Fremgangsmåde til fremstilling af formylnitrilderivater.
DK140551C (da) Fremgangsmaade til fremstilling af diazabicycloalkanderivater